Investigating how c-Myc affects cancer treatment with EGFR inhibitors
c-Myc modulation and its implications in EGFR-targeted cancer therapy
This study is looking into how the c-Myc gene affects the treatment of non-small cell lung cancer, especially for patients who aren't responding well to the drug osimertinib, with the hope of finding better ways to help those who have developed resistance to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10873110 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the c-Myc gene in the treatment of non-small cell lung cancer (NSCLC) using epidermal growth factor receptor (EGFR) inhibitors. It aims to explore why some patients develop resistance to the FDA-approved drug osimertinib, which is used for treating EGFR mutant NSCLC. By studying the mechanisms behind this resistance, the research seeks to identify new strategies to enhance treatment effectiveness. Patients may benefit from insights that could lead to improved therapies for those who have become resistant to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer who have EGFR mutations and have developed resistance to previous EGFR-targeted therapies.
Not a fit: Patients with non-cancerous conditions or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with resistant non-small cell lung cancer.
How similar studies have performed: Previous research has shown promising results in targeting c-Myc in cancer therapies, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Sun, Shi-Yong — Emory University
- Study coordinator: Sun, Shi-Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.